
Opinion|Videos|October 7, 2024
PSMA PET Imaging and Radioligand Therapy in mCRPC: Insights From VISION and TheraP Trials
Author(s)Neal Shore, MD, FACS
Key Takeaways
Neal Shore, MD, FACS, discusses how the patient profile in the VISION trial, which involved progression on multiple therapies, reflects typical cases for Lutetium-177 treatment, emphasizing the crucial role of PSMA PET imaging in determining treatment suitability.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Clinical Application of MMAI Score in Patients with Prostate Cancer
2
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
3
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
4
Benjamin Lowentritt, MD, reviews real-world testosterone recovery data with relugolix
5







